IP Library › Granted Patent US 10,106,603
Granted Patent B2
US 10,106,603 · App. 15/988,463 · Granted Oct 23, 2018

Treatment of fibrosis

Inventors: Stuart Alexander Cook (Singapore, SG); Sebastian Schaefer (Singapore, SG)
Assignees: Singapore Health Services PTE LTD; National University of Singapore
C07K16/244A61K2039/505A61K2039/54C07K2317/20C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,603
App. No.
15/988,463
Granted
Oct 23, 2018
Kind
B2
Abstract

Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Claims (10)

1. A method of treating fibrosis in the human subject, the method comprising administering to a human subject in need of treatment a therapeutically effective amount of an Interleukin 11 receptor α (IL-11Rα) antibody which is capable of inhibiting Interleukin 11 (IL-11) mediated signaling, wherein the fibrosis is fibrosis of the heart, liver, kidney or eye.

2. The method of claim 1 , wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

3. The method of claim 1 , wherein the antibody is an IL-11Rα binding antibody.

4. The method of claim 1 , wherein the fibrosis is in the heart and is associated with dysfunction of the musculature or electrical properties of the heart, or thickening of the walls or valves of the heart.

5. The method of claim 1 , wherein the fibrosis is in the liver and is associated with chronic liver disease or liver cirrhosis.

6. The method of claim 1 , wherein the fibrosis is in the kidney and is associated with chronic kidney disease.

7. The method of claim 1 , wherein the fibrosis is in the eye and is retinal fibrosis, epiretinal fibrosis, or subretinal fibrosis.

8. The method of claim 1 , wherein the method of treating fibrosis comprises administering said antibody to a subject in which IL-11Rα expression is upregulated.

9. The method of claim 1 , wherein the method of treating fibrosis comprises administering said antibody to a subject in which IL-11Rα expression has been determined to be upregulated.

10. The method of claim 1 , wherein the method of treating fibrosis comprises determining whether IL-11Rα expression is upregulated in the subject and administering said antibody to a subject in which IL-11Rα expression is upregulated.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2018
From: COOK, STUART ALEXANDER
To: NATIONAL UNIVERSITY OF SINGAPORE; SINGAPORE HEALTH SERVICES PTE LTD
Reel/Frame 045988/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2018
From: SCHAEFER, SEBASTIAN
To: NATIONAL UNIVERSITY OF SINGAPORE; SINGAPORE HEALTH SERVICES PTE LTD
Reel/Frame 045988/0374 →
Priority Claims (1)
GB 1522186.4 · Dec 16, 2015 · national
Continuity (2)
Division 15381622 · Dec 16, 2016
Related Publication 20180265579A1 · Sep 20, 2018